Clinical Trial

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Examine the effects of deutetrabenazine on functional speech and gait impairment
Protocol Amendment History 3 changes
notable Primary completion pushed: 2026-06-30 -> 2027-06-30 2026-08-06
minor Completion pushed: 2026-10-01 -> 2027-10-01 2026-08-06
notable Primary completion pushed: 2026-03 -> 2026-06-30 2026-04-15
Trial Details
NCT Number NCT04713982
Lead Sponsor Vanderbilt University Medical Center
Collaborators: Teva Branded Pharmaceutical Products R&D, Inc.
Conditions Huntington Disease
Enrollment 30 participants
Start Date 2021-11-19
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-05